Akira Takahashi

8PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 05, 2026
Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: a Multicenter Prospective Observational Study (COSMOS-MEL01).

|Dec 14, 2022
Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma.

Akira Takahashi, Kenjiro Namikawa, Dai Ogata

|Jul 30, 2020
Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma.

Akira Takahashi, Kenjiro Namikawa, Dai Ogata

|Mar 20, 2020
Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.

Haruki Mizuta, Eiji Nakano, Akira Takahashi

|Mar 13, 2020
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.

Eiji Nakano, Akira Takahashi, Kenjiro Namikawa

|Dec 27, 2019
Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.

Akira Takahashi, Kenjiro Namikawa, Eiji Nakano

Pageof 2

Frequent Collaborators

7 joint publications

Kenjiro Namikawa

6 joint publications

Naoya Yamazaki

5 joint publications

Eiji Nakano

3 joint publications

Shunichi Jinnai